Linezolid bested vancomycin for treatment of nosocomial pneumonia due to MRSA

Links shared publicly online about this topic.

759
total visits

Linezolid bested vancomycin for treatment of nosocomial pneumonia due to MRSA

IDSA 48th Annual Meeting Linezolid had an end-of-study success rate that was more than 10% higher than vancomycin in patients with nosocomia

View full resource at pediatricsupersite.com

Tags: MRSA, Pneumonia, Antibiotic, Zyvox, Vancomycin

Most Recently Shared on November 1, 2010 at 4:08 pm By:

Pediatric SuperSite

#Linezolid bested #vancomycin for treatment of nosocomial pneumonia due to #MRSA: http://ow.ly/32C7Q

1 year ago...

Retweet

Favorite

Zyvox achieves higher clinical success rate than vancomycin in MRSA nosocomial pneumonia study

news-medical.net — “Results of a new international phase 4 study of patients with nosocomial pneumonia due to proven methicillin-resistant Staphylococcus aureus (MRSA) demonstrated that the antibiotic Zyvox® (linezolid) achieved a statistically significantly higher clinical success rate compared with vancomycin for the primary endpoint. The ZEPHyR (Linezolid in the treatment of subjects with nosocomial pneumonia proven to be due to methicillin-resistant Staphylococcus aureus) study was the largest ever conduct” View full resource at news-medical.net